Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.

Kleiblova P, Stolarova L, Krizova K, Lhota F, Hojny J, Zemankova P, Havranek O, Vocka M, Cerna M, Lhotova K, Borecka M, Janatova M, Soukupova J, Sevcik J, Zimovjanova M, Kotlas J, Panczak A, Vesela K, Cervenkova J, Schneiderova M, Burocziova M, Burdova K, Stranecky V, Foretova L, Machackova E, Tavandzis S, Kmoch S, Macurek L, Kleibl Z.

Int J Cancer. 2019 May 3. doi: 10.1002/ijc.32385. [Epub ahead of print]

PMID:
31050813
2.

Co-targeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma.

Prukova D, Andera L, Nahacka Z, Karolova J, Svaton M, Klanova M, Havranek O, Soukup J, Svobodova K, Zemanova Z, Tuskova D, Pokorna E, Helman K, Forsterova K, Pacheco-Blanco M, Vockova P, Berkova A, Fronkova E, Trneny M, Klener P.

Clin Cancer Res. 2019 Apr 19. pii: clincanres.3275.2018. doi: 10.1158/1078-0432.CCR-18-3275. [Epub ahead of print]

PMID:
31004002
3.

B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia.

Vangapandu HV, Havranek O, Ayres ML, Kaipparettu BA, Balakrishnan K, Wierda WG, Keating MJ, Davis RE, Stellrecht CM, Gandhi V.

Mol Cancer Res. 2017 Dec;15(12):1692-1703. doi: 10.1158/1541-7786.MCR-17-0026. Epub 2017 Aug 23.

4.

Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.

Havranek O, Xu J, Köhrer S, Wang Z, Becker L, Comer JM, Henderson J, Ma W, Man Chun Ma J, Westin JR, Ghosh D, Shinners N, Sun L, Yi AF, Karri AR, Burger JA, Zal T, Davis RE.

Blood. 2017 Aug 24;130(8):995-1006. doi: 10.1182/blood-2016-10-747303. Epub 2017 Jun 23.

5.

Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.

Mathur R, Sehgal L, Havranek O, Köhrer S, Khashab T, Jain N, Burger JA, Neelapu SS, Davis RE, Samaniego F.

Haematologica. 2017 Feb;102(2):373-380. doi: 10.3324/haematol.2016.144964. Epub 2016 Oct 14.

6.

Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.

Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Jäger U, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin KM, Müschen M, Meyer LH, Davis RE, Burger JA.

Leukemia. 2016 Jun;30(6):1246-54. doi: 10.1038/leu.2016.9. Epub 2016 Feb 5.

7.

Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma.

Havranek O, Kleiblova P, Hojny J, Lhota F, Soucek P, Trneny M, Kleibl Z.

PLoS One. 2015 Oct 27;10(10):e0140819. doi: 10.1371/journal.pone.0140819. eCollection 2015.

8.

Is there an intermediate-risk non-seminoma? long-term treatment results from a single center.

Cvek J, Feltl D, Hajek J, Jackaninova J, Ruzickova K, Havranek O, Dvorackova J, Dobes P.

J BUON. 2014 Jul-Sep;19(3):775-9.

9.

Fistula between anterior rectum wall and seminal vesicles as a rare complication of low-anterior resection of the rectum.

Sýkora R, Krhut J, Jonszta T, Němec D, Havránek O, Martínek L.

Wideochir Inne Tech Maloinwazyjne. 2012 Mar;7(1):63-6. doi: 10.5114/wiitm.2011.25715. Epub 2011 Nov 14.

10.

Alterations of CHEK2 forkhead-associated domain increase the risk of Hodgkin lymphoma.

Havranek O, Spacek M, Hubacek P, Mocikova H, Markova J, Trneny M, Kleibl Z.

Neoplasma. 2011;58(5):392-5.

PMID:
21744992
11.

No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphoma.

Havranek O, Spacek M, Hubacek P, Mocikova H, Benesova K, Soucek P, Trneny M, Kleibl Z.

Leuk Res. 2011 Aug;35(8):1117-9. doi: 10.1016/j.leukres.2011.04.001. Epub 2011 May 5.

PMID:
21546086
12.

[Combination therapy with anticholinergics and alpha-blockers for the treatment of overactive bladder in female patients--pilot study].

Krhut J, Gärtner M, Havránek O, Nemec D, Tvrdík J.

Ceska Gynekol. 2009 Dec;74(6):416-20. Czech.

PMID:
21246788
13.

CHEK2 gene alterations in the forkhead-associated domain, 1100delC and del5395 do not modify the risk of sporadic pancreatic cancer.

Mohelnikova-Duchonova B, Havranek O, Hlavata I, Foretova L, Kleibl Z, Pohlreich P, Soucek P.

Cancer Epidemiol. 2010 Oct;34(5):656-8. doi: 10.1016/j.canep.2010.06.008.

PMID:
20643596
14.

The AIB1 gene polyglutamine repeat length polymorphism and the risk of breast cancer development.

Kleibl Z, Havranek O, Kormunda S, Novotny J, Foretova L, Machackova E, Soukupova J, Janatova M, Tavandzis S, Pohlreich P.

J Cancer Res Clin Oncol. 2011 Feb;137(2):331-8. doi: 10.1007/s00432-010-0889-5. Epub 2010 Apr 27.

PMID:
20422428
15.

[Present view on the diagnostics and treatment of nocturia].

Zachoval R, Krhut J, Havránek O, Záleský M.

Cas Lek Cesk. 2010;149(12):576-9. Review. Czech.

PMID:
21387583
16.

[Efficacy and safety of solifenacin in daily clinical practice--clinical study phase IV].

Krhut J, Havránek O, Míka D, Fabisovský M, Valis P.

Ceska Gynekol. 2008 Dec;73(6):370-5. Czech.

PMID:
19170373
17.

The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population.

Kleibl Z, Havranek O, Hlavata I, Novotny J, Sevcik J, Pohlreich P, Soucek P.

Eur J Cancer. 2009 Mar;45(4):618-24. doi: 10.1016/j.ejca.2008.09.022. Epub 2008 Nov 6.

PMID:
18996005
18.

Analysis of CHEK2 FHA domain in Czech patients with sporadic breast cancer revealed distinct rare genetic alterations.

Kleibl Z, Havranek O, Novotny J, Kleiblova P, Soucek P, Pohlreich P.

Breast Cancer Res Treat. 2008 Nov;112(1):159-64. Epub 2007 Dec 4.

PMID:
18058223
19.

Rapid detection of CAA/CAG repeat polymorphism in the AIB1 gene using DHPLC.

Kleibl Z, Havranek O, Prokopcova J.

J Biochem Biophys Methods. 2007 Apr 10;70(3):511-3. Epub 2006 Dec 9.

PMID:
17234271

Supplemental Content

Loading ...
Support Center